PALOMA-3 Trial

[Slide 1] PALOMA-3 PALOMA-3: Phase 3 Study Design Ami Lazin 3LEGFR+ NSCLC Key eligibility criteria SC Amivantamab + Lazertinib Co-primary endpointsᶜ: Locally advanced or metastatic NSCLC 1:1 randomization (n=206) Ctrough (noninferiority)d Disease had progressed on or after osimertinib and platinum- (N=418) C2 AUC (noninferiority) based chemotherapy, IV Amivantamab + Lazertinib irrespective of order Secondary endpoints: Documented EGFR Ex19del (n=212) ORR (noninferiority) or L858R Dosing (in 28-day cycles) PFS (superiority) ECOG PS 0-1 SC Amivantamab (co-formulated with rHuPH20 and DoR Stratification factors administered by manual injection): 1600 mg (2240 mg if Patient satisfaction Brain metastases (yes or no) >80 kg) weekly for the first 4 weeks, then every 2 weeks thereafter EGFR mutation type (Ex19del Safety vs L858R) IV Amivantamab 1050 mg weekly (1400 mg if >80 kg) for the first 4 weeks, then every 2 weeks thereafter Race (Asian vs non-Asian) Lazertinib: 240 mg PO daily Exploratory endpoints: Type of last therapy OS (osimertinib vs chemotherapy) Prophylactic anticoagulation recommended for the first 4 months of treatment PALOMA (ClinicalTrials gov identifier (105388669) enrollment period August 2022 to October 2023; data outcif Jan 2024 PSC amivantamab ass 00 formulated with #HuPH20 at concentration of 160 mg/mL C1 for IV Days 110 2 (Day applies to IV aplit dose only (350 mg on Day and the remainder on Day 20. 8, 15. and 22. C1 for sc Days 1,8, 15 and 22. after C1 for at Days 1 and 15 (28-day cycles) For calculating primary and key secondary outcomes, we estimated that sample size of 400 patients would provide +95% power for sided alpha of 0.05 allocated to each of the co-primary endpoints and 80% power with sided alpha of 0.025 allocated to ORR hierarchical testing approach at 12 sided alpha of 0.05 NOS used for the 00 primary endpoints (noninferionly). followed by ORR (nonintenonty) and PFS (superiority). with combined sided alpha of 0.05 Two definitions of the same endpoint were used as per regional health authority guidance "Measured between C2D1 and C2D15 Assessed by modified TASQ AUC area under the concentration time curve C. Cycle Changh observed serum concentration of amivantamob at steady state 0. Day. DoR, duration of response ECOG PS, Eastem Cooperative Oncology Group performance status EGFR epidemal growth factor receptor Extidet Exon 19 deletion N. intravenous NSCLC non-small cell lung cancer ORR, objective response rate OS, overall survival PFS. progression-free survival PO. orally, rHuPH20. hyaluronidase SC. subcutaneous TASQ Therapy Administration Satisfaction Questionnaire 2024 ASCO PRE SENTED BY: Natasha 8 Leighl Copies of this stide deck obtained through Quick Response (QR) ASCO AMERICAN SOCIETY #ASCO24 Code are for personal use only and may not be reproduced without CUNICAL ONCOLOGY ANNUAL MEETING Presentation property of the author and ASCO Permission required for - contact permissions@asco.org DATE permission from ASCO or the authors of these sides KNOWLEDGE CONQUERS CANCER 2024 ASCO ANNUAL MEETING

[Slide 1] PALOMA-3 Co-primary PK Endpoints Met Noninferiority Criteria Ami Lazin 3L EGFR+ NSCLC Cₜᵣₒugh at C2D1 C2 AUCD₁-D₁₅ Geometric mean ratio=1.15 Geometric mean ratio=1.03 (90% CI, 1.04-1.26) (90% CI, 0.98-1.09) 800 350,000 700 300,000 600 250,000 Observed Cough of amivantamab (µg/mL) 500 400 300 AUCO1.015 of amivantamab (ug-h/mL) 200,000 150,000 100,000 200 100 50,000 0 0 SC Amivantamab Arm IV Amivantamab Arm SC Amivantamab Arm IV Amivantamab Arm (n=160) (n=142) (n=140) (n=132) Geometric mean ratio for Ctrough at steady state (C4D1) was 1.43 (90% CI, 1.27-1.61) Note: The pharmacokinetic analysis for primary endpoints included all patients who received all doses without dose modification and provided the required PK samples through the final required PK sample relevant to the endpoint The upper and lower ends of the boxes indicate the 25th and 75th quarties, the triangles indicate the means, the horizontal lines within the boxes indicate the medians, and the error bars indicate 95% Cls AUC, area under the concentration time curve; C. Cycle: CI, confidence interval Crass observed serum concentration of amivantamab at steady state: D. Day, IV, intravenous PK pharmacokinetic SC. subcutaneous 2024 ASCO PRESENTED BY: Natasha B Leighl Copies of this side deck obtained through Quick Response (QR) ASCO AMERICAN SOCIETY OF #ASCO24 Code are for personal use only and may not be reproduced without CLINICAL ONCOLOGY ANNUAL MEETING Presentation is property of the author and ASCO Permission required for reuse contact permissions@asco.org permission from ASCO or the authors of these stides KNOWLEDGE CONQUERS CANCER --- [Slide 2] PALOMA-3 ORR and DoR Ami Lazir 3L EGFR+ NSCLC ORR was noninferior between the SC and IV amivantamab arms DoR was 11.2 months in the SC arm VS 8.3 months in the IV arm, with twice as many patients, 29% in the SC arm VS 14% in the IV arm, having a response ≥6 months DoR SC Amivantamab IV Amivantamab 100 Arm (n=206) Arm (n=212) ORR, % (95% CI)ᵃ 80 30 (24-37) 33 (26-39) All responders Relative risk, 0.92 (95% CI, 0.70-1.23); P=0.001 Patients who are responding (%) SC Amivantamab Arm 60 Confirmed 27 (21-33) 27 (21-33) IV Amivantamab Arm responders Relative risk, 0.99 (95% CI, 0.72-1.36); P<0.001 Best response, n (%) 40 Median DoR CR 1 (0.5) 1 (0.5) Median follow-up: 7.0 mo (95% CI) PR 61 (30) 68 (32) 20 SC Amivantamab Arm 11.2 mo (6.1-NE) SD 93 (45) 81 (38) IV Amivantamab Arm 8.3 mo (5.4-NE) PD 37 (18) 42 (20) 0 0 2 4 6 8 10 12 Not evaluable 14 (7) 20 (9) DCR, % (95% CI)b 75 (69-81) 71 (64-77) Months from date of first response Median time to No at risk 1.5 (1.2-6.9) 1.5 (1.2-9.9) SC Amivantamab Arm 55 47 30 16 11 2 0 response (range), mo IV Amivantamab Arm 57 47 25 8 4 0 0 "The objective response (CR or PR) was assessed using RECIST v1.1 and analyzed using logistic regression The lower bound of the 95% CI indicated >70% retention of CRR exceeding the predefined 60% retention assumed for determining noninferionly. Not protocol specified CI, confidence interval; CR, complete response DCR disease control rate (CR+PR+SD): DoR, duration of response, IV, intravenous; mo, months; NE, not estimable; ORR, objective response rate; PR, partial response RECIST, Response Evaluation Criteria in Solid Tumors SC, subcutaneous; SD, stable disease 2024 ASCO PRESENTED BY: Natasha B Leighl Copies of this slide deck obtained through Quick Response (QR) #ASCO24 ASCO AMERICAN SOCIETY OF Code are for personal use only and may not be reproduced without CLINICAL ONCOLOGY ANNUAL MEETING Presentation is property of the author and ASCO Permission required for reuse; contact permissions@asco permission from ASCO or the authors of these sides KNOWLEDGE CONQUERS CANCER --- [Slide 3] PALOMA-3 Progression-free Survival Ami Lazin 3L EGFR+ NSCLC PFS was numerically longer with SC VS IV amivantamab, with an HR of 0.84 100 Median PFS Median follow-up: 7.0 mo (95% CI) SC Amivantamab Arm 6.1 mo (4.3-8.1) 80 IV Amivantamab Arm 4.3 mo (4.1-5.7) Patients who are progression-free (%) HR, 0.84 (95% CI, 0.64-1.10); P=0.20 60 50% 37% 40 42% SC Amivantamab Arm 20 IV Amivantamab Arm 20% 0 0 2 4 6 8 10 12 14 16 Months No. at risk SC Amivantamab Arm 206 153 116 57 37 14 3 0 0 IV Amivantamab Arm 212 154 109 43 23 7 3 0 0 Note: The efficacy population included all the patients who had undergone randomization PFS was tested for superiority as part of the hierarchical testing strategy, P value was calculated from a rank test stratified by history of train metastases Asian race, EGFR mutation type (Ex19del or L858R). and last line of therapy (osimertinib or platinum based therapy). CI, confidence interval; EGFR epidermal growth factor receptor, Ex19del Exon 19 deletion; HR, hazard ratio; IV, intravenous mo, months; PFS, progression free survival SC. subcutaneous 2024 ASCO #ASCO24 PRESENTED BY: Natasha B Leighl Copies of this slide deck obtained through Quick Response (QR) ASCO AMERICAN SOCIETY OF Code are for personal use only and may not be reproduced without CLINICAL ONCOLOGY ANNUAL MEETING Presentation is property of the author and ASCO Permission required for reuse; contact permissions@asco.co permission from ASCO or the authors of these slides KNOWLEDGE CONQUERS CANCER --- [Slide 4] PALOMA-3 Overall Survival Ami Laz in 3LEGFR+NSCLC There was an OS benefit associated with SC amivantamab, with an HR of 0.62 compared to the IV amivantamab armᵃ Median follow-up: 7.0 mo 100 HR, 0.62 (95% CI, 0.42-0.92); nominal P=0.02 85% 80 65% 75% Patients who are alive (%) SC Amivantamab Arm 60 IV Amivantamab Arm 51% 40 20 0 0 2 4 6 8 10 12 14 16 Months No. at risk SC Amivantamab Arm 206 192 163 109 71 36 10 0 0 IV Amivantamab Arm 212 191 144 92 51 24 10 1 0 Note: The efficacy population included all the patients who had undergone randomization There were 43 deaths in the SC amivantamab arm and 62 deaths in the IV amivantamab arm Nominal P value was calculated from a log rank test stratified by history of brain metastases Asian race, EGFR mutation type (Ex19del or L858R). and last line of therapy (osimertinib or platinum-based therapy). the prespecified endpoint was exploratory and not part of hierarchical hypothesis testing CI, confidence interval EGFR epidermal growth factor receptor, Ex19del Exon 19 deletion HR hazard ratio; IV, intravenous mo. months OS, overall survival SC, subcutaneous 2024 ASCO PRESENTED BY: Natasha B Leighl Copies of this slide deck obtained through Quick Response (QR) ASCO AMERICAN SOCIETY OF #ASCO24 Code are for personal use only and may not be reproduced without CLINICAL ONCOLOGY ANNUAL MEETING Presentation is property of the author and ASCO. Permission required for reuse, contact permissions@asco org permission from ASCO or the authors of these stides KNOWLEDGE CONQUERS CANCER

[Slide 1] ASCO ® AD Subcutaneous amivantamab ... vs intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Primary results, including overall survival (OS), from the global, phase 3, randomized controlled PALOMA-3 trial. Abstract Authors Natasha B. Leighl i Princess Margaret Cancer Centre, Toronto, ON, Canada

[Slide 1] PALOMA-3 2024 ASCO ANNUAL MEETING Subcutaneous amivantamab vs intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated, advanced non-small cell lung cancer Primary results, including overall survival, from the global, phase 3, randomized controlled PALOMA-3 trial Natasha B Leight, Hiroaki Akamatsu,2 Sun Min Lim,3 Ying Cheng.4 Anna R Minchom,5 Melina E Marmarelis, Rachel E Sanborn,7 James Chih-Hsin Yang,8 Baogang Liu,9 Thomas John,10 Bartomeu Massuti,11 Alexander I Spira,12 John Xie, 13 Debopriya Ghosh, 13 Ali Alhadab,14 Remy B Verheijen, 15 Mohamed Gamil,16 Joshua M Bauml, 16 Mahadi Baig,¹³ Antonio Passaro17 Princess Margaret Cancer Centre, Toronto, ON, Canada; internal Medicine III, Wakayama Medical University Wakayama, Japan Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea "Jilin Cancer Hospital, Changchun China Drug Development Unit The Royal Marsden Hospital and The Institute of Cancer Research, Sutton, UK; "Division of Hematology and Oncology Department of Medicine, Perelman School of Medicine, University of Pennsylvania Philadelphia, PA USA 'Earle A Chiles Research Institute, Providence Cancer Institute, Portland, OR, USA; "Department of Medical Oncology National Taiwan University Cancer Center, Taipoi, Taiwan Harbin Medical University Cancer Hospital, Harbin China Peter MacCallum Cancer Centre, The University of Melbourne, Melbourne, Australia "Alicante University Dr Balmis Hospital ISABIAL Alicante, Spain Vrgina Cancer Specialists Fairfax, VA USA "Janssen Research & Development Raritan, NJ, USA; "Janssen Research & Development San Diego, CA, USA; "Janssen Research & Development Leiden, The Netherlands, "Janssen Research & Development Spring House, PA USA; "European Institute of Oncology IRCCS, Milano, Italy. 2024 ASCO #ASCO24 PRESENTED BY BY: Natasha B Leight Copes of the - deck oblaned through Quex Response (OR) Code are for personal - any not reproduced without ASCO ANNUAL MEETING I i - - - permission ASCOR the authors here andes KNOWLEDGE CONQUERS CANCER --- [Slide 2] PALOMA-3 PALOMA-3: Phase 3 Study Design Ami Laz in 3LEGFR+NSCLC Key eligibility criteria SC Amivantamab + Lazertinib Co-primary endpointsᶜ: Locally advanced or metastatic NSCLC 1:1 randomization (n=206) Ctrough (noninferiority)d Disease had progressed on or after osimertinib and platinum- (N=418) C2 AUC (noninferiority) based chemotherapy, IV Amivantamab + Lazertinib irrespective of order Secondary endpoints: Documented EGFR Ex19del (n=212) ORR (noninferiority) or L858R Dosing (in 28-day cycles) PFS (superiority) ECOG PS 0-1 SC Amivantamab® (co-formulated with rHuPH20 and DoR Stratification factors administered by manual injection): 1600 mg (2240 mg if Patient satisfaction Brain metastases (yes or no) >80 kg) weekly for the first 4 weeks, then every 2 weeks thereafter EGFR mutation type (Ex19del Safety vs L858R) IV Amivantamabb: 1050 mg weekly (1400 mg if >80 kg) for the first 4 weeks, then every 2 weeks thereafter Race (Asian vs non-Asian) Lazertinib: 240 mg PO daily Exploratory endpoints: Type of last therapy OS (osimertinib vs chemotherapy) Prophylactic anticoagulation recommended for the first 4 months of treatment PALOMA-3 (Clinical Trials gov Identifier NCT05388669) enrollment period August 2022 to October 2023, data outoff 03-Jan-2024 *SC amivantamab was 00- formulated with fHuPH20 at a concentration of 160 mg/mL °C1 for IV Days to 2 (Day 2 applies to IV split dose only [350 mg on Day 1 and the remainder on Day 2D. 8. 15, and 22. C1 for SC: Days 1,8, 15, and 22. after C1 for all Days 1 and 15 (28-day cycles) For calculating primary and key secondary outcomes, we estimated that a sample size of 400 patients would provide >95% power for a 1-sided alpha of 0.05 allocated to each of the co-primary endpoints and 80% power with a 1-sided alpha of 0.025 allocated to ORR A hierarchical testing approach at 2. sided alpha of 0.05 was used for the co-primary endpoints (noninferiority). followed by ORR (noninferiority) and PFS (superiority). with a combined 2-sided alpha of 0.05 Two definitions of the same endpoint were used as per regional health authority guidance "Measured between C2D1 and C2D15 Assessed by modified TASQ AUC. area under the concentration-time curve, C, Cycle: Crough observed serum concentration of amivantamab at steady state: D. Day, DoR, duration of response, ECOG PS, Eastern Cooperative Oncology Group performance status: EGFR epidermal growth factor receptor, Ex19del Exon 19 deletion; IV, intravenous NSCLC, non-small cell lung cancer, ORR, objective response rate; OS, overall survival; PFS, progression-free survival; PO, orally, rHuPH20, hyaluronidase; SC, subcutaneous; TASQ Therapy Administration Satisfaction Questionnaire 2024 ASCO #ASCO24 PRESENTED B BY: Natasha B Leight Copies of this stude deck obtained through Quick Response (QR) Code are for personal use only and may not be reproduced without ASCO AMERICAN SOCIETY OF CLINICAL ONCOLOGY ANNUAL MEETING Presentation - property of the author and ASCO Permission required for reuse contact permissions@asco.org permission from ASCO* or the authors of these sides KNOWLEDGE CONQUERS CANCER --- [Slide 3] PALOMA-3 ORR and DoR Ami Laz in LEGFR+ NSCLC ORR was noninferior between the SC and IV amivantamab arms DoR was 11.2 months in the SC arm vs 8.3 months in the IV arm, with twice as many patients, 29% in the SC arm vs 14% in the IV arm, having a response ≥6 months DoR SC Amivantamab IV Amivantamab 100 Arm (n=206) Arm (n=212) ORR, % (95% CI)* 80 30 (24-37) All responders 33 (26-39) Relative risk, 0.92 (95% CI, 0.70-1.23); P=0.001 Patients who are responding (%) SC Amivantamab Arm 60 Confirmed 27 (21-33) 27 (21-33) IV Amivantamab Arm responders Relative risk, 0.99 (95% CI, 0.72-1.36); P<0.001 Best response, n (%) 40 Median DoR CR 1 (0.5) 1 (0.5) Median follow-up: 7.0 mo (95% CI) PR 61 (30) 68 (32) 20 SC Amivantamab Arm 11.2 mo (6.1-NE) SD 93 (45) 81 (38) IV Amivantamab Arm 8.3 mo (5.4-NE) PD 37 (18) 42 (20) 0 0 2 4 6 8 10 12 Not evaluable 14 (7) 20 (9) DCR, % (95% CI)ᵇ 75 (69-81) 71 (64-77) Months from date of first response Median time to No. at risk 1.5 (1.2-6.9) 1.5 (1.2-9.9) SC Amivantamab Arm 55 47 30 16 11 2 0 response (range), mo IV Amivantamab Arm 57 47 25 8 4 0 0 "The objective response (CR or PR) was assessed using RECIST v1 and analyzed using logistic regression The lower bound of the 95% CI indicated >70% retention of ORR exceeding the predefined 60% retention assumed for determining noninferiority Not protocol specified CI, confidence interval, CR, complete response DCR, disease control rate (CR*PR*SD) DoR, duration of response; IV, intravenous; mo, months; NE, not estimable; ORR, objective response rate; PR partial response, RECIST, Response Evaluation Criteria in Solid Tumors: SC, subcutaneous; SD, stable disease SENTED BY: Natasha B Leight Copies of this sade deck obtained through Quick Response (QR) 2024 ASCO ASCO AMERICAN SOCIETY OF #ASCO24 Code are for personal use only and may not be reproduced without CLINICAL ONCOLOGY ANNUAL MEETING Presentation . property of the author and ASCO Permission required for reuse contact permissions@asco.org permission from ASCO* or the authors of these sides KNOWLEDGE CONQUERS CANCER --- [Slide 4] PALOMA-3 Overall Survival Ami+Lazin 3LEGFR+NSCLC There was an os benefit associated with SC amivantamab, with an HR of 0.62 compared to the IV amivantamab armª 100 Median follow-up: 7.0 mo HR, 0.62 (95% CI, 0.42-0.92); nominal P=0.02 85% 80 65% Patients who are alive (%) 75% SC Amivantamab Arm 60 IV Amivantamab Arm 51% 40 20 0 0 2 4 6 8 10 12 14 16 Months No. at risk SC Amivantamab Arm 206 192 163 109 71 36 10 0 0 IV Amivantamab Arm 212 191 144 92 51 24 10 1 0 Note: The efficacy population included all the patients who had undergone randomization There were 43 deaths in the SC amivantamab arm and 62 deaths in the IV amivantamab arm Nominal P value was calculated from a log-rank test stratified by history of brain metastases Asian race, EGFR mutation type (Ex19del or LBSBR), and last line of therapy (osimertinib or platinum-based therapy). the prespecified endpoint was exploratory and not part of hierarchical hypothesis testing CL, confidence interval EGFR, epidermal growth factor receptor, Ex196l Exon 19 deletion HR, hazard ratio; IV, intravenous; mo, months; OS, overall survival; SC, subcutaneous 2024 ASCO #ASCO24 PRE SENTED BY: Natasha B Leight Copies of this slide deck obtained through Quick Response (QR) Code are for personal use only and may not be reproduced without ASCO AMERICAN SOCIETY OF CLINICAL ONCOLOGY ANNUAL MEETING Presentation is property of the author and ASCO Permission required for reuse, contact permissions@asco org. permission from ASCO* or the authors of these sides KNOWLEDGE CONQUERS CANCER

[Slide 1] Paloma-3 data Endpoint SC Rybrevant + lazertinib IV Rybrevant + lazertinib 30% 33% ORR Relative risk, 0.92; p=0.001* mDoR 11.2mo 8.3mo 6.1mo 4.3mo PFS HR: 0.84; p=0.20** OS HR: 0.62; nominal p=0.017 Infusion-related reactions 13% 66% VTE 9% 14% Notes: *met non-inferiority criteria; **trend in favour of SC. Source: ASCO 2024.

[Slide 1] PALOMA-3 ORR and DoR Ami Laz in 3L EGFR+ NSCLC ORR was noninferior between the SC and IV amivantamab arms DoR was 11.2 months in the SC arm VS 8.3 months in the IV arm, with twice as many patients, 29% in the SC arm vs 14% in the IV arm, having a response 6 months DoR SC Amivantamab IV Amivantamab 100 au Arm (n=206) Arm (n=212) ORR, % (95% CI) 80 30 (24-37) 33 (26-39) All responders SC Amivantamab Arm Relative risk, 0.92 (95% CI, 0.70-1.23); P=0.001 60 Confirmed 27 (21-33) 27 (21-33) IV Amivantamab Arm responders Relative risk, 0.99 (95% CI, 0.72-1.36); P<0.001 Best response, n (%) 40 Median DoR CR 1 (0.5) 1 (0.5) Median follow-up: 7.0 mo (95% CI) PR 61 (30) 68 (32) 20 SC Amivantamab Arm 11.2 mo (6.1-NE) SD 93 (45) 81 (38) IV Amivantamab Arm 8.3 mo (5.4-NE) PD 37 (18) 42 (20) 0 0 2 4 6 8 10 12 Not evaluable 14 (7) 20 (9) DCR, % (95% CI)b 75 (69-81) 71 (64-77) Months from date of first response Median time to No at risk 1.5 (1.2-6.9) 1.5 (1.2-9.9) SC Amivantamab Arm 55 47 30 16 11 2 0 response (range), mo IV Amivantamab Arm 57 47 25 8 4 0 0 "The objective response (CR or PR) was assessed using RECIST v1.1 and analyzed using logistic regression The lower bound of the 95% CI indicated >70% retention of ORR exceeding the predefined 60% retention assumed for determining noninferiority Not protocol specified CI. confidence interval CR complete response DCR disease control rate (CR+PR+SD) DoR duration of response IV. intravenous mo. months NE not estimable ORR objective response rate: PR partial response RECIST Response Evaluation Criteria in Solid Tumors; SC. subcutaneous SD stable disease 2024 ASCO PRESENTED BY: Natasha B Leigh Copies of this slide deck obtained through Quick Response (QR) #ASCO24 ASCO AMERICAN SOCIETY OF Code are for personal use only and may not be reproduced without CLINICAL ONCOLOGY ANNUAL MEETING Presentation is property of the author and ASCO Permission required for reuse contact permissions@asco.c org permission from ASCO or the authors of these slides KNOWLEDGE CONQUERS CANCER --- [Slide 2] PALOMA-3 Adverse Event of Special Interest: VTE Ami Laz in 3L EGFR NSCLC Prophylactic anticoagulation was administered to 80% (164/206) of patients in the SC arm and 81% (171/210) for IV Among all patients in the study, VTE was reported in 10% (32/335) of those receiving prophylactic anticoagulation vs 21% (17/81) who did not Rates of grade 3 bleeding events were uncommon in the SC (2%) and IV (1%) arms for those receiving prophylactic anticoagulation Rates of VTE by Treatment Arm and Prophylaxis Status 50 SC Ami IV Ami Grade >3 40 Grade 2 Between study arms, incidence of VTE Grade 1 was less frequent in the SC amivantamab 30 26% arm compared to the IV arm, regardless of prophylactic anticoagulation status 20 17% 14% 12% 9% 10 7% 0 n=206 n=210 n=164 n=171 n=42 n=39 All patients On prophylactic No prophylactic anticoagulation anticoagulation Note: The safety population included all the patients who had undergone randomization and received at least one dose of any trial treatment Grouping includes pulmonary embolism deep vein thrombosis venous embolism venous thrombosis limb, embolism thrombosis, subclavian vein thrombosis, superficial vein thrombosis pulmonary infarction venous thrombosis VVE prophylaxis with apixaban, rivaroxaban, dalteparin, or enoxaparin was recommended by protocol (per the National Comprehensive Cancer Network guideline Cancer-Associated Venous Thromboembolic Disease v1 2022) IV. intravenous SC. subcutaneous VTE venous thromboembolism 2024 ASCO PRESENTED BY: Natasha B Leight Copies of this slide deck obtained through Quick Response (QR) #ASCO24 Code are for personal use only and may not be reproduced without ASCO AMERICAN SOCIETY OF CLINICAL ONCOLOGY ANNUAL MEETING Presentation is property of the author and ASCO Permission required for reuse; contact permissions@asco.org permission from ASCO or the authors of these slides KNOWLEDGE CONQUERS CANCER --- [Slide 3] PALOMA-3 Overall Survival Ami Laz 3LEGFR+NSCLC There was an os benefit associated with SC amivantamab, with an HR of 0.62 compared to the IV amivantamab arm Median follow-up: 7.0 mo 100 HR, 0.62 (95% CI, 0.42-0.92); nominal P=0.02 85% -LL III III 80 IIII 65% 75% ILL SC Amivantamab Arm 60 111 IV Amivantamab Arm 51% 40 20 0 0 2 4 6 8 10 12 14 16 Months No. at risk SC Amivantamab Arm 206 192 163 109 71 36 10 0 0 IV Amivantamab Arm 212 191 144 92 51 24 10 1 0 Note: The efficacy population included all the patients who had undergone randomization "There were 43 deaths in the SC amivantamab arm and 62 deaths in the IV amivantamab arm Nominal P value was calculated from log-rank test stratified by history of brain metastases Asian race EGFR mutation type (Ex19del or L858R) and last line of therapy (osimertinib or platinum-based therapy) the prespecified endpoint was exploratory and not part of hierarchical hypothesis testing CI, confidence interval; EGFR, epidermal growth factor receptor, Ex19del Exon 19 deletion; HR hazard ratio; IV, intravenous mo. months OS, overall survival SC subcutaneous 2024 ASCO PRESENTED BY: Natasha B Leigh Copies of this slide deck obtained through Quick Response (QR) ASCO AMERICAN SOCIETY OF CLINICAL ONCOLOGY #ASCO24 Code are for personal use only and may not be reproduced without ANNUAL MEETING Presentation is property of the author and ASCO Permission required for reuse contact permissions@asco.org permission from ASCO or the authors of these slides KNOWLEDGE CONQUERS CANCER

[Slide 1] PALOMA-3 ORR and DoR Ami Lazin ORR was noninferior between the SC and IV amivantamab arms DoR was 11.2 months in the SC arm vs 8.3 months in the IV arm, with twice as many patients, 29% in the SC arm vs 14% in the IV arm, having a response >6 months DoR SC Amivantamab IV Amivantamab 100 Arm (n=206) Arm (n=212) ORR, % (95% CI)* 80 All responders 30 (24-37) 33 (26-39) Relative risk, 0.92 (95% CI, 0.70-1.23); P=0.001 Patients who are responding (%) SC Amivantamab Arm Confirmed 60 27 (21-33) 27 (21-33) IV Amivantamab Arm responders Relative risk, 0.99 (95% CI, 0.72-1.36); P<0.001 Best response, n (%) 40 CR Median DoR 1 (0.5) 1 (0.5) Median follow-up: 7.0 mo (95% CI) PR 61 (30) 68 (32) 20 SC Amivantamab Arm 11.2 mo (6.1-NE) SD 93 (45) 81 (38) IV Amivantamab Arm 8.3 mo (5.4-NE) PD 37 (18) 42 (20) 0 0 2 4 6 8 10 12 Not evaluable 14 (7) 20 (9) DCR, % (95% CI)ᵇ 75 (69-81) 71 (64-77) Months from date of first response Median time to No at risk 1.5 (1.2-6.9) 1.5 (1.2-9.9) SC Amwantamab Arm 55 47 30 16 " 2 0 response (range), mo IV Amwantamab Arm 57 47 25 8 4 0 0 The objective response (CR or PR) - assessed using RECIST v1. 1 and analyzed using logistic regression. The lower bound of the 95% CI indicated >70% retention of ORR exceeding the predetined 60% retention assumed for determining nonintenority Not protocol specified. CL confidence interval, CR, complete response, DCR, disease control rate (CR*PR*5D). DoR, duration of response, N. intravenous, mo, months NE, not estimable ORR objective response rate, PR partial response, RECIST, Response Evaluation Cetana in Sold Tumors BC, so, stable disease 2024 ASCO SENTED BY: Natasha B Leight Copies of this sale deck octained through Quick Response (QR) #ASCO24 ASCO AMERICAN SOCIETY OF Code are for personal use only and may not be reproduced without CURICAL ONCOLOGY ANNUAL MEETING Presentation . property of the author and ASCO Permission required for reuse contact permissors@asco.org permission from ASCO® or the authors of these sides. KNOWLEDGE CONQUERS CANCER --- [Slide 2] PALOMA-3 Progression-free Survival Am Lastin 3LEGFR> NSCLO PFS was numerically longer with SC VS IV amivantamab, with an HR of 0.84 100 Median PFS Median follow-up: 7.0 mo (95% CI) SC Amivantamab Arm 6.1 mo (4.3-8.1) 80 IV Amivantamab Arm 4.3 mo (4.1-5.7) Patients who are progression-free (%) HR, 0.84 (95% CI, 0.64-1.10): P=0.20 60 50% 40 BELIL 37% 42% EL 111 SC Amivantamab Arm 20 IV Amivantamab Arm 20% 0 0 2 4 6 8 10 12 14 16 Months No. at risk SC Amivantamab Arm 206 153 116 57 37 14 3 0 0 IV Amivantamab Arm 212 154 109 43 23 7 3 0 0 Note: The efficacy population included all the patients who had undergone randomization. PFS was tested for superiority as part of the hierarchical testing strategy, P value was calculated from # log-rank test stratfied by history of train metastases, Asian race, EGFR motation type (Ex19del or LASBR), and last line of therapy (osimentinib or platinum-based therapy). CL, confidence interval, EGFR epidemal growth factor receptor, Extidel Exon 19 deletion, HR hazard ratio, IV, intravenous; mo, months PFS, progression-free survival, SC, subculaneous. 2024 ASCO PRE SENTED BY: Natasha B Leight Copies of this sade deck obtained through Quick Response (OR) Code are for personal use only and may not be reproduced without ASCO AMERICAN SOCIETY or #ASCO24 CUMICAL ONCOLOGY ANNUAL MEETING Presentation . preperty of the author and ASCO Permission required for - contact permissions@asco.org permission from ASCO* or the authors of these sides KNOWLEDGE CONQUERS CANCER --- [Slide 3] PALOMA-3 Overall Survival Ani - Lazin 3. EGFR> NSCI There was an OS benefit associated with SC amivantamab, with an HR of 0.62 compared to the IV amivantamab arm" 100 Median follow-up: 7.0 mo HR, 0.62 (95% CI, 0.42-0.92); nominal P=0.02 85% 80 65% Patients who are alive (%) 75% SC Amivantamab Arm 60 IV Amivantamab Arm 51% 40 20 0 0 2 4 6 8 10 12 14 16 Months No. at risk SC Amivantamab Arm 206 192 163 109 71 36 10 0 0 IV Amivantamab Arm 212 191 144 92 51 24 10 1 0 Note: The efficacy population included all the patients who had undergone randomization "There were 43 deaths in the SC anivantamab am and 62 deaths in the IV amivantamab am Nominal P value was calculated from . log-rank test stratified by history of brain metastases, Asian nce EGFR mutation type (Ex 19del or LBSBR). and last line of therapy (osimenting or platinum-based therapy): the prespecified endpoint was exploratory and not part of herathical hypothesis testing CI, confidence interval, EGFR epidemal growth factor receptor, Ext9del Exon 19 deletion HR hazard ratio, IV, intravenous mo, months OS, overall survival SC, subcutaneous 2024 ASCO PRE SENTED BY: Natasha B Leight Copies of this sade deck ottained through Quick Response (OR) ASCO AMERICAN SOCIETY OF #ASCO24 Code are for personal use only and may not be reproduced without CURICAL ONCOLOGY ANNUAL MEETING Presentation a property of the author and ASCO Permission required for reuse, contact permissions@ass.org permission from ASCO* or the authors of these sides KNOWLEDGE CONQUERS CANCER --- [Slide 4] PALOMA-3 Incidence of IRR-related Symptoms Ami Lazin 3. EGFR> NSCLC SC Amivantamab Arm IV Amivantamab Arm (n=206) (n=210) IRRs were observed in 13% of IRRs, all grades 13% 66% IRRs, grade 3 0. 4% patients in the SC arm vs 66% in Infusion-related the IV arm, representing a 5-fold AEs (≥2%) reduction Chills 6% 14% Pyrexia 3% 3% There were no grade 4 or 5 Dyspnea 3% 20% IRRs Nausea 3% 20% Vomiting 2% 15% Most IRRs occurred during Cough 2% 8% Hypoxia Cycle 1 2% 9% Hypotension 1% 8% Sinus tachycardia 2% 5% IRRs leading to hospitalization Erythema 1% 3% Chest discomfort were not observed in the SC arm 0.5% 6% Hypertension 0.5% 6% vs 2 events in the IV arm Flushing 12% Dizziness 4% Rash 3% No IRR-related discontinuations Hyperhidrosis 2% occurred in the SC arm vs 4 Increased heart rate 2% events in the IV arm 100% 75% 50% 25% 0% 25% 50% 75% 100% Note: The safety population included all the patients who had undergone randomization and received 21 done of any trial treatment AE, adverse event, IRR, infusion-related reaction; IV, intravenous; SO, subcutaneous 2024 ASCO PRESENTED BY: Natasha B Leight Copies of this side deck obtained through Quick Response (OR) #ASCO24 ASCO AMERICAN SOCIETY OF Code are for personal use enty and may not be reproduced without CURRICAL ONCOLOGY ANNUAL MEETING Presentation is property of the author and ASCO Permission required for mm contact permissions@asco.org permission from ASCO* or the authors of these stides KNOWLEDGE CONQUERS CANCER

[Slide 1] Treatment Administration Time and Convenience Treatment administration time was reduced to less than 5 minutes for SC amivantamab from 5 hours for the first infusion (2 hours for subsequent infusions) for IV amivantamab More patients reported their administration method to be convenient or very convenient with SC VS IV amivantamab Frequency of Patient-reported Convenience per Modified TASQª 100 P<0.001 P<0.001 90 80 Patient-reported convenience (%)b 70 60 50 40 85% 85% 30 52% 20 35% 10 0 SC Amivantamab IV Amivantamab SC Amivantamab IV Amivantamab Arm Arm Arm Arm (n=193) (n=195) (n=61) (n=51) C1D1d EOTe Response categories on the modified TASQ convenience question included "Very convenient", "Convenient", "Neither convenient nor inconvenient", "Inconvenient", and "Very Inconvenient". *Includes patients whose answer was "Very convenient" or "Convenient." **P values were nominal and obtained by Pearson's chi-squared test. C1D2 for patients who received IV amivantamab due to split dosing. "Could have been collected after the last dose of treatment. C, Cycle; D, Day; EOT, end of treatment; IV, intravenous; SC, subcutaneous; TASQ. Treatment Administration Satisfaction Questionnaire. 14 Presented : by NB Leight at the American Society 1 of Clinical Oncology (ASCO) Annual Meeting: May 31-June 4, 2024: Chicago, IL, USA --- [Slide 2] Conclusions SC amivantamab + lazertinib demonstrated PK and ORR noninferiority to IV amivantamab + lazertinib in patients with EGFR-mutated advanced NSCLC with disease progression on or after osimertinib and chemotherapy Compared to the IV arm, SC amivantamab also showed: - Numerically longer DoR (11.2 VS 8.3 months) and PFS (6.1 VS 4.3 months) - Significant improvement in OS (HR, 0.62; nominal P=0.02) Future studies are needed to evaluate if SC absorption via the lymphatic system enhances amivantamab's immune-mediated activity The safety profile of SC amivantamab was consistent with IV, with fewer IRRs (13% VS 66%) and VTE (9% VS 14%) Administration time was substantially shorter for SC amivantamab (median <5 minutes) VS IV amivantamab (ranging from 2 to 5 hours), with significantly more patients reporting convenience (85% VS 35% at EOT) SC amivantamab + lazertinib provided noninferior efficacy, lower rates of IRRs and VTE, and is more convenient for patients and providers vs IV amivantamab + lazertinib DoR, duration of response; EGFR, epidermal growth factor receptor; EOT, end of treatment; HR, hazard ratio; IRR, infusion-related reaction; IV, intravenous; NSCLC, non-smal cell lung cancer; ORR, objective response rate; OS, overall survivat PFS, progression-free survivat PK, pharmacokinetic; SC, subcutaneous; VTE, venous thromboembolism. 15 Presented by NB Leight at the American Society of Clinical Oncology (ASCO) Annual Meeting: May 31-June 4, 2024; Chicago, IL, USA